Skip to content
Study details
Enrolling now

Phase 1 Trial of SBS-147 in Healthy Adults

Sparian Biosciences, Inc
NCT IDNCT07335913ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1

Target enrollment

80

Study length

about 1.1 years

Ages

18–55

Locations

1 site in CA

About this study

This trial is testing the safety and how people's bodies react to SBS-147. Participants will receive either SBS-147 or a placebo, which looks like SBS-147 but has no medicine. The study involves both a single dose and multiple doses of SBS-147 over 409 days.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take Placebo
  • 2.Take SBS-147
PhasePhase 1
Primary goalNumber of participants with treatment-related adverse events as assessed by CTCAE v5.0

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low15%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Endpoints

Primary: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0, Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 at ascending doses

Secondary: Plasma pharmacokinetics of SBS-1000 and SBS-147 following multiple ascending doses